Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: Randomised clinical trial

BMJ

Volumn 337, Issue 7663, 2008, Pages 220-223

  Nunn, Andrew J ^a   Mwaba, Peter ^b   Chintu, Chifumbe ^b   Mwinga, Alwyn ^b   Darbyshire, Janet H ^a   Zumla, Alimuddin ^c  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MORTALITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ZAMBIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; DOUBLE-BLIND METHOD; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; TUBERCULOSIS, PULMONARY;

EID: 48349126520     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a257     Document Type: Article

References (10)

1. Joint United Nations Programme on HIV/AIDS, World Health Organization. Provisional WHO/UNAIDS Secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Geneva: UNAIDS, 2000 (available at http://data.unaids.org/ Publications/IRC-pub04/recommendation_en.pdf).
2. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 1999;353:1469-75.
3. Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999;353:1463-8.
4. Maynart M, Lièvre L, Sow PS, Kony S, Gueye NF, Bassène E, et al. Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. J Acquir Immune Defic Syndr 2001;26:130-6.
5. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. Co-trimoxazole prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double blind randomised placebo-controlled trial. Lancet 2004;364:1865-71.
6. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF. Effectiveness of co-trimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005;19:163-8.
7. Zachariah R, Spielmann MP, Chinji C, Gomani P, Arendt V, Hargreaves NJ, et al. Voluntary counselling, HIV testing and adjunctive co-trimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003;17:1053-61.
8. Mwaungulu FB, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyongoloka H, et al. Co-trimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ 2004;82:354-63.
9. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4 cell count and viral load in HIV infection in rural Uganda. Lancet 2004;364:1428-34.
10. World Health Organization. TB/HIV research priorities in resource-limited settings: report of an expert consultation. Geneva: WHO, 2005 (available at http://whqlibdoc.who.int/hq/2005/WHO_HTM_TB_2005.355.pdf).